Lake Street analyst Brooks O'Neil says Diplomat Pharmacy is well positioned as pending mergers bring changes to the healthcare marketplace. The company's PBM/Specialty Pharmacy/Home Infusion businesses are "strategically and financially attractive" and pending consolidation creates "attractive scarcity," which will benefit Diplomat materially, O'Neil tells investors in a research note. Further, he believes recent management changes and acquisitions at the company create an opportunity for outperformance. He keeps a Buy rating on Diplomat Pharmacy with a $35 price target.